Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant‐ineligible patients with myeloma who are treated with bortezomib‐based induction-Reference-Cited by-同舟云学术

Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant‐ineligible patients with myeloma who are treated with bortezomib‐based induction

Published:2021-06-26 Issue:4 Volume:107 Page:497-499
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Boyle Stephen¹^ORCID,Wellard Cameron²,Moore Elizabeth M.²,Blacklock Hilary³,Harrison Simon J.⁴,Ho Phoebe Joy⁵,Hocking Jay⁶,McQuilten Zoe K.²,Quach Hang⁷,Spearing Ruth⁸,Wood Erica M.²,Spencer Andrew⁹,Mollee Peter¹,

Affiliation:

1. Princess Alexandra Hospital The University of Queensland Brisbane QLD Australia

2. School of Public Health and Preventive Medicine Monash University Melbourne VIC Australia

3. Middlemore Hospital Auckland New Zealand

4. Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne HospitalSir Peter MacCallum Department of OncologyUniversity of Melbourne Melbourne VIC Australia

5. Royal Prince Alfred Hospital Camperdown NSW Australia

6. Box Hill Hospital Melbourne VIC Australia

7. University of MelbourneSt. Vincent’s Hospital Melbourne VIC Australia

8. Christchurch Hospital Christchurch New Zealand

9. The Alfred HospitalMonash University and Australian Centre for Blood Diseases Melbourne VIC Australia

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13677

Reference6 articles.